Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2026)

Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 34, which is 6 points higher than the diagnostic & research industry average of 28.

CDNA passed 11 out of 33 due diligence checks and has average fundamentals. Caredx has seen its stock return 37.8% over the past year, overperforming other diagnostic & research stocks by 22 percentage points.

Caredx has an average 1 year price target of $24.50, an upside of 7.36% from Caredx's current stock price of $22.82.

Caredx stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Caredx, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Billiontoone (NASDAQ:BLLN) is the #2 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Billiontoone (NASDAQ:BLLN) is: Value: C, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Billiontoone (NASDAQ:BLLN) has a Due Diligence Score of 11, which is -17 points lower than the diagnostic & research industry average of 28. Although this number is below the industry average, our proven quant model rates BLLN as a "B".

BLLN passed 3 out of 33 due diligence checks and has weak fundamentals.

Billiontoone has an average 1 year price target of $125.29, an upside of 26.56% from Billiontoone's current stock price of $98.99.

Billiontoone stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Billiontoone, 71.43% have issued a Strong Buy rating, 0% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Labcorp Holdings (NYSE:LH) is the #3 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Labcorp Holdings (NYSE:LH) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: C, and AI: C.

Labcorp Holdings (NYSE:LH) has a Due Diligence Score of 47, which is 19 points higher than the diagnostic & research industry average of 28.

LH passed 17 out of 38 due diligence checks and has strong fundamentals. Labcorp Holdings has seen its stock return 5.39% over the past year, underperforming other diagnostic & research stocks by -11 percentage points.

Labcorp Holdings has an average 1 year price target of $314.00, an upside of 20.74% from Labcorp Holdings's current stock price of $260.06.

Labcorp Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Labcorp Holdings, 25% have issued a Strong Buy rating, 50% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.67%, which is 1 percentage points higher than the diagnostic & research industry average of 0.82%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 35.6% indicates that its dividend yield is sustainable for the long-term.

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.11%, which is the same as the diagnostic & research industry average of 0.82%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 25.4% indicates that its dividend yield is sustainable for the long-term.

Danaher (NYSE:DHR) has an annual dividend yield of 0.74%, which is the same as the diagnostic & research industry average of 0.82%. Danaher's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Danaher's dividend has shown consistent growth over the last 10 years.

Danaher's dividend payout ratio of 26.2% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were up 0.75% in the last day, and up 6.91% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has dropped -18.69% in the past year. It has underperformed other stocks in the diagnostic & research industry by -35 percentage points.

Icon (NASDAQ:ICLR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 44 points higher than the diagnostic & research industry average of 13. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has gained 3.81% in the past year. It has underperformed other stocks in the diagnostic & research industry by -12 percentage points.

Danaher (NYSE:DHR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Danaher has a valuation score of 14, which is 1 points higher than the diagnostic & research industry average of 13. It passed 1 out of 7 valuation due diligence checks.

Danaher's stock has dropped -4.1% in the past year. It has underperformed other stocks in the diagnostic & research industry by -20 percentage points.

54.76% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 18.36% over the next year.

2.27% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 18.18% of diagnostic & research stocks are rated B (Buy), 63.64% are rated C (Hold), 13.64% are rated D (Sell), and 2.27% are rated F (Strong Sell).